FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4361946818> ?p ?o ?g. }

• W4361946818 abstract "<div>AbstractPurpose:<p>Pembrolizumab improved survival in patients with recurrent or metastatic head and neck squamous-cell carcinoma (HNSCC). The aims of this study were to determine if pembrolizumab would be safe, result in pathologic tumor response (pTR), and lower the relapse rate in patients with resectable human papillomavirus (HPV)–unrelated HNSCC.</p>Patients and Methods:<p>Neoadjuvant pembrolizumab (200 mg) was administered and followed 2 to 3 weeks later by surgical tumor ablation. Postoperative (chemo)radiation was planned. Patients with high-risk pathology (positive margins and/or extranodal extension) received adjuvant pembrolizumab. pTR was quantified as the proportion of the resection bed with tumor necrosis, keratinous debris, and giant cells/histiocytes: pTR-0 (<10%), pTR-1 (10%–49%), and pTR-2 (≥50%). Coprimary endpoints were pTR-2 among all patients and 1-year relapse rate in patients with high-risk pathology (historical: 35%). Correlations of baseline PD-L1 and T-cell infiltration with pTR were assessed. Tumor clonal dynamics were evaluated (ClinicalTrials.gov NCT02296684).</p>Results:<p>Thirty-six patients enrolled. After neoadjuvant pembrolizumab, serious (grades 3–4) adverse events and unexpected surgical delays/complications did not occur. pTR-2 occurred in eight patients (22%), and pTR-1 in eight other patients (22%). One-year relapse rate among 18 patients with high-risk pathology was 16.7% (95% confidence interval, 3.6%–41.4%). pTR ≥10% correlated with baseline tumor PD-L1, immune infiltrate, and IFNγ activity. Matched samples showed upregulation of inhibitory checkpoints in patients with pTR-0 and confirmed clonal loss in some patients.</p>Conclusions:<p>Among patients with locally advanced, HPV-unrelated HNSCC, pembrolizumab was safe, and any pathologic response was observed in 44% of patients with 0% pathologic complete responses. The 1-year relapse rate in patients with high-risk pathology was lower than historical.</p></div>" @default.
• W4361946818 created "2023-04-05" @default.
• W4361946818 creator A5004313839 @default.
• W4361946818 creator A5005477709 @default.
• W4361946818 creator A5005956102 @default.
• W4361946818 creator A5008214979 @default.
• W4361946818 creator A5012365084 @default.
• W4361946818 creator A5013133259 @default.
• W4361946818 creator A5017340351 @default.
• W4361946818 creator A5018145418 @default.
• W4361946818 creator A5019133023 @default.
• W4361946818 creator A5020521476 @default.
• W4361946818 creator A5021329688 @default.
• W4361946818 creator A5022139249 @default.
• W4361946818 creator A5024024612 @default.
• W4361946818 creator A5026148495 @default.
• W4361946818 creator A5027605173 @default.
• W4361946818 creator A5027679923 @default.
• W4361946818 creator A5035700326 @default.
• W4361946818 creator A5036875036 @default.
• W4361946818 creator A5036890758 @default.
• W4361946818 creator A5040514240 @default.
• W4361946818 creator A5045619380 @default.
• W4361946818 creator A5047622041 @default.
• W4361946818 creator A5047966818 @default.
• W4361946818 creator A5049138316 @default.
• W4361946818 creator A5049794515 @default.
• W4361946818 creator A5051302491 @default.
• W4361946818 creator A5051793744 @default.
• W4361946818 creator A5052134884 @default.
• W4361946818 creator A5052720205 @default.
• W4361946818 creator A5054429419 @default.
• W4361946818 creator A5058907044 @default.
• W4361946818 creator A5058975989 @default.
• W4361946818 creator A5063558685 @default.
• W4361946818 creator A5064319129 @default.
• W4361946818 creator A5066002385 @default.
• W4361946818 creator A5070027862 @default.
• W4361946818 creator A5072207500 @default.
• W4361946818 creator A5072448404 @default.
• W4361946818 creator A5076166380 @default.
• W4361946818 creator A5080875822 @default.
• W4361946818 creator A5082271196 @default.
• W4361946818 creator A5083874204 @default.
• W4361946818 creator A5084494097 @default.
• W4361946818 creator A5087519887 @default.
• W4361946818 date "2023-03-31" @default.
• W4361946818 modified "2023-09-28" @default.
• W4361946818 title "Data from Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus–Unrelated Head and Neck Cancer: A Multicenter, Phase II Trial" @default.
• W4361946818 doi "https://doi.org/10.1158/1078-0432.c.6529716" @default.
• W4361946818 hasPublicationYear "2023" @default.
• W4361946818 type Work @default.
• W4361946818 citedByCount "0" @default.
• W4361946818 crossrefType "posted-content" @default.
• W4361946818 hasAuthorship W4361946818A5004313839 @default.
• W4361946818 hasAuthorship W4361946818A5005477709 @default.
• W4361946818 hasAuthorship W4361946818A5005956102 @default.
• W4361946818 hasAuthorship W4361946818A5008214979 @default.
• W4361946818 hasAuthorship W4361946818A5012365084 @default.
• W4361946818 hasAuthorship W4361946818A5013133259 @default.
• W4361946818 hasAuthorship W4361946818A5017340351 @default.
• W4361946818 hasAuthorship W4361946818A5018145418 @default.
• W4361946818 hasAuthorship W4361946818A5019133023 @default.
• W4361946818 hasAuthorship W4361946818A5020521476 @default.
• W4361946818 hasAuthorship W4361946818A5021329688 @default.
• W4361946818 hasAuthorship W4361946818A5022139249 @default.
• W4361946818 hasAuthorship W4361946818A5024024612 @default.
• W4361946818 hasAuthorship W4361946818A5026148495 @default.
• W4361946818 hasAuthorship W4361946818A5027605173 @default.
• W4361946818 hasAuthorship W4361946818A5027679923 @default.
• W4361946818 hasAuthorship W4361946818A5035700326 @default.
• W4361946818 hasAuthorship W4361946818A5036875036 @default.
• W4361946818 hasAuthorship W4361946818A5036890758 @default.
• W4361946818 hasAuthorship W4361946818A5040514240 @default.
• W4361946818 hasAuthorship W4361946818A5045619380 @default.
• W4361946818 hasAuthorship W4361946818A5047622041 @default.
• W4361946818 hasAuthorship W4361946818A5047966818 @default.
• W4361946818 hasAuthorship W4361946818A5049138316 @default.
• W4361946818 hasAuthorship W4361946818A5049794515 @default.
• W4361946818 hasAuthorship W4361946818A5051302491 @default.
• W4361946818 hasAuthorship W4361946818A5051793744 @default.
• W4361946818 hasAuthorship W4361946818A5052134884 @default.
• W4361946818 hasAuthorship W4361946818A5052720205 @default.
• W4361946818 hasAuthorship W4361946818A5054429419 @default.
• W4361946818 hasAuthorship W4361946818A5058907044 @default.
• W4361946818 hasAuthorship W4361946818A5058975989 @default.
• W4361946818 hasAuthorship W4361946818A5063558685 @default.
• W4361946818 hasAuthorship W4361946818A5064319129 @default.
• W4361946818 hasAuthorship W4361946818A5066002385 @default.
• W4361946818 hasAuthorship W4361946818A5070027862 @default.
• W4361946818 hasAuthorship W4361946818A5072207500 @default.
• W4361946818 hasAuthorship W4361946818A5072448404 @default.
• W4361946818 hasAuthorship W4361946818A5076166380 @default.
• W4361946818 hasAuthorship W4361946818A5080875822 @default.
• W4361946818 hasAuthorship W4361946818A5082271196 @default.
• W4361946818 hasAuthorship W4361946818A5083874204 @default.
• W4361946818 hasAuthorship W4361946818A5084494097 @default.
• W4361946818 hasAuthorship W4361946818A5087519887 @default.
• W4361946818 hasBestOaLocation W43619468182 @default.
• W4361946818 hasConcept C121608353 @default.

• next